Foghorn Therapeutics (FHTX) Competitors

Foghorn Therapeutics logo
$1.76 -0.03 (-1.40%)
As of 12:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

FHTX vs. MDXG, YDES, AVTE, PRTA, and KMDA

Should you buy Foghorn Therapeutics stock or one of its competitors? Foghorn Therapeutics's main competitors and comparable companies include MiMedx Group (MDXG), YD Bio (YDES), Aerovate Therapeutics (AVTE), Prothena (PRTA), and Kamada (KMDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Foghorn Therapeutics compare to MiMedx Group?

MiMedx Group (NASDAQ:MDXG) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

MiMedx Group presently has a consensus price target of $8.14, indicating a potential upside of 164.81%. Foghorn Therapeutics has a consensus price target of $6.14, indicating a potential upside of 250.02%. Given Foghorn Therapeutics' higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than MiMedx Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiMedx Group
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Foghorn Therapeutics
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.27

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MiMedx Group has higher revenue and earnings than Foghorn Therapeutics. MiMedx Group is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiMedx Group$418.63M1.07$48.58M-$0.13N/A
Foghorn Therapeutics$30.91M3.40-$74.28M$0.0725.07

MiMedx Group has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 3.22, meaning that its stock price is 222% more volatile than the broader market.

In the previous week, MiMedx Group had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 4 mentions for MiMedx Group and 3 mentions for Foghorn Therapeutics. MiMedx Group's average media sentiment score of 0.35 beat Foghorn Therapeutics' score of 0.31 indicating that MiMedx Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiMedx Group
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Foghorn Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Foghorn Therapeutics has a net margin of 8.40% compared to MiMedx Group's net margin of -6.32%. MiMedx Group's return on equity of 2.39% beat Foghorn Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MiMedx Group-6.32% 2.39% 1.85%
Foghorn Therapeutics 8.40%-13.46%4.63%

Summary

MiMedx Group and Foghorn Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to YD Bio?

YD Bio (NASDAQ:YDES) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Foghorn Therapeutics has a net margin of 8.40% compared to YD Bio's net margin of 0.00%. YD Bio's return on equity of 0.00% beat Foghorn Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
YD BioN/A N/A N/A
Foghorn Therapeutics 8.40%-13.46%4.63%

YD Bio has higher earnings, but lower revenue than Foghorn Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
YD BioN/AN/AN/AN/AN/A
Foghorn Therapeutics$30.91M3.40-$74.28M$0.0725.07

YD Bio has a beta of -1.2, suggesting that its stock price is 220% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 3.22, suggesting that its stock price is 222% more volatile than the broader market.

Foghorn Therapeutics has a consensus price target of $6.14, suggesting a potential upside of 250.02%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than YD Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
YD Bio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Foghorn Therapeutics
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.27

In the previous week, Foghorn Therapeutics had 2 more articles in the media than YD Bio. MarketBeat recorded 3 mentions for Foghorn Therapeutics and 1 mentions for YD Bio. Foghorn Therapeutics' average media sentiment score of 0.31 beat YD Bio's score of 0.22 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
YD Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Foghorn Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

61.6% of Foghorn Therapeutics shares are owned by institutional investors. 9.0% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Foghorn Therapeutics beats YD Bio on 11 of the 12 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

61.6% of Foghorn Therapeutics shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Foghorn Therapeutics had 3 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 3 mentions for Foghorn Therapeutics and 0 mentions for Aerovate Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.31 beat Aerovate Therapeutics' score of 0.00 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aerovate Therapeutics Neutral
Foghorn Therapeutics Neutral

Foghorn Therapeutics has a consensus price target of $6.14, suggesting a potential upside of 250.02%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Foghorn Therapeutics
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.27

Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 3.22, meaning that its stock price is 222% more volatile than the broader market.

Foghorn Therapeutics has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A
Foghorn Therapeutics$30.91M3.40-$74.28M$0.0725.07

Foghorn Therapeutics has a net margin of 8.40% compared to Aerovate Therapeutics' net margin of 0.00%. Foghorn Therapeutics' return on equity of -13.46% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aerovate TherapeuticsN/A -90.19% -77.47%
Foghorn Therapeutics 8.40%-13.46%4.63%

Summary

Foghorn Therapeutics beats Aerovate Therapeutics on 14 of the 15 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Prothena?

Prothena (NASDAQ:PRTA) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Foghorn Therapeutics has a net margin of 8.40% compared to Prothena's net margin of -45.44%. Prothena's return on equity of -9.98% beat Foghorn Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Prothena-45.44% -9.98% -9.08%
Foghorn Therapeutics 8.40%-13.46%4.63%

Foghorn Therapeutics has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prothena$9.68M43.65-$244.09M-$0.48N/A
Foghorn Therapeutics$30.91M3.40-$74.28M$0.0725.07

Prothena has a beta of -0.2, meaning that its stock price is 120% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 3.22, meaning that its stock price is 222% more volatile than the broader market.

In the previous week, Prothena and Prothena both had 3 articles in the media. Prothena's average media sentiment score of 0.58 beat Foghorn Therapeutics' score of 0.31 indicating that Prothena is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prothena
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Foghorn Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

97.1% of Prothena shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Prothena currently has a consensus target price of $20.00, indicating a potential upside of 143.07%. Foghorn Therapeutics has a consensus target price of $6.14, indicating a potential upside of 250.02%. Given Foghorn Therapeutics' higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than Prothena.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prothena
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67
Foghorn Therapeutics
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.27

Summary

Foghorn Therapeutics beats Prothena on 9 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Kamada?

Foghorn Therapeutics (NASDAQ:FHTX) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

61.6% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 9.0% of Foghorn Therapeutics shares are held by insiders. Comparatively, 36.1% of Kamada shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Kamada has higher revenue and earnings than Foghorn Therapeutics. Kamada is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Foghorn Therapeutics$30.91M3.40-$74.28M$0.0725.07
Kamada$180.46M2.48$20.20M$0.4318.13

Kamada has a net margin of 12.67% compared to Foghorn Therapeutics' net margin of 8.40%. Kamada's return on equity of 9.36% beat Foghorn Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Foghorn Therapeutics8.40% -13.46% 4.63%
Kamada 12.67%9.36%6.53%

In the previous week, Kamada had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 4 mentions for Kamada and 3 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.31 beat Kamada's score of 0.00 indicating that Foghorn Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Foghorn Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kamada
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Foghorn Therapeutics presently has a consensus target price of $6.14, indicating a potential upside of 250.02%. Kamada has a consensus target price of $13.75, indicating a potential upside of 76.40%. Given Foghorn Therapeutics' higher probable upside, equities research analysts clearly believe Foghorn Therapeutics is more favorable than Kamada.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Foghorn Therapeutics
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.27
Kamada
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Foghorn Therapeutics has a beta of 3.22, indicating that its share price is 222% more volatile than the broader market. Comparatively, Kamada has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Summary

Kamada beats Foghorn Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Foghorn Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FHTX vs. The Competition

MetricFoghorn TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$105.23M$3.96B$7.48B$11.10B
Dividend YieldN/A3.64%2.48%4.74%
P/E Ratio25.0823.7332.6829.17
Price / Sales3.4015.508.125.38
Price / CashN/A22.6520.7221.66
Price / Book-7.634.194.353.55
Net Income-$74.28M-$23.99M$3.50B$393.99M
7 Day Performance-15.22%-8.11%-6.86%-7.60%
1 Month Performance-12.69%-13.46%-9.85%-10.97%
1 Year Performance-61.76%-6.94%-2.38%-8.48%

Foghorn Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FHTX
Foghorn Therapeutics
3.7327 of 5 stars
$1.76
-1.4%
$6.14
+250.0%
-63.4%$105.23M$30.91M25.08106
MDXG
MiMedx Group
2.668 of 5 stars
$3.37
+1.5%
$8.14
+141.6%
-52.0%$484.47M$418.63MN/A808
YDES
YD Bio
1.1851 of 5 stars
$6.03
-10.1%
N/AN/A$475MN/AN/A14
AVTE
Aerovate Therapeutics
N/A$15.60
+3.5%
N/A+23.0%$452.17MN/AN/A20
PRTA
Prothena
2.9815 of 5 stars
$8.56
-2.4%
$20.00
+133.6%
-15.9%$450.59M$9.68MN/A67

Related Companies and Tools


This page (NASDAQ:FHTX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners